CD226 and sarcoma: In line with the observed expression of DNAM-1 receptor ligands CD112 and CD155 (Figure 2C), DNAM-1+ GM NK-92 cells degranulated significantly against all 12 sarcoma explants and cell lines, while NKG2D+ GM NK-92 cells degranulated more than 20% to 10 out of 12 (p-values in Table S1).